Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. PANW
3. CL
4. SNDK
5. TAP
6. DELL
7. ROIV
8. ANET
9. NKE
10. BLDR

Go back to Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
(NASDAQ: DNTH) Delayed: 108.10 +0.25 (0.23%)
Previous Close $107.85    52 Week High $ 
Open $107.06    52 Week Low $ 
Day High $109.61    P/E N/A 
Day Low $105.65    EPS $ 
Volume 638,560